|
|
Blood, Vol. 111, Issue 6, 3116-3125, March 15, 2008
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines
Blood Ahonen et al.
111: 3116
Supplemental materials for: Ahonen et al
Files in this Data Supplement:
- Figure S1. Route of immunization does not impact therapeutic benefit (JPG, 54.7 KB)
-
C57BL/6 mice were challenged with 1 × 105 metastatic B16.F10 melanoma cells i.v. Four days later, mice were vaccinated with 100 µg  CD40 FGK45 i.p. plus 100 µg of the tumor associated antigen  V and 100 µg S-27609 given intraperitoneally (IP), subcutaneously (Subq) or intravenously (IV). After 20 days, mice were euthanized, lungs removed and metastatic surface tumor nodules were enumerated with the aid of a dissecting microscope. Data are representative of 2 experiments with 4-8 mice per group. Significance was assessed by ANOVA and Tukey analysis. p values of less than 0.05 were considered significant.
- Figure S2. αCD40/TLR7* therapeutic intervention slows progression of metastatic melanoma (JPG, 61.2 KB)
-
C57BL/6 mice were challenged with 1 × 105 metastatic B16.F10 melanoma cells i.v. Four days later, mice were vaccinated with 100 µg of the tumor associated antigen V, 100 µg CD40 FGK45 and 100 µg S-27609 in combinations as indicated. Kaplan Meier plots show survival over time. Data are pooled from 3-4 independent experiments with greater than 8 mice per group in each experiment. p=>0.0001 for V versus V/CD40 and p=<0.0003 for V/CD40 versus V/CD40/TLR7* as assessed by log rank analysis.
|
|
